Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study

NCT02782182 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Closed early due to poor accrual.

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

DRUG: FOLFIRINOX (oxaliplatin, leucovorin, irinotecan)

Sponsor

University of Chicago